Inmed Pharmaceuticals Inc. (IMLFF) 0.1954 $IMLFF
InMed Pharmaceuticals Strengthens Scientific Advisory Board
PR Newswire - Tue Mar 31, 7:00AM CDT
InMed Pharmaceuticals Inc. ("InMed"

(CSE: IN; OTCQB: IMLFF), a clinical stage biopharmaceutical company that specializes in developing safer, more effective cannabis-based therapies, today announced the appointment of Paul C. Anderson, Ph.D., to its Scientific Advisory Board. Dr. Anderson is a pharma industry veteran who brings significant drug discovery and development expertise to InMed.
InMed Receives Exemption Status from Health Canada
Marketwired - Mon Mar 23, 7:02AM CDT
InMed Pharmaceuticals Inc. ("InMed"

(CSE: IN)(OTCQB: IMLFF), a clinical stage biopharmaceutical company that specializes in developing safer, more effective cannabis-based therapies, today announced that it has received a notice from Health Canada dated March 12, 2015, approving InMed's application for an exemption under Section 56 of the Controlled Drugs and Substances Act.
2015-0319 - Index - CSE Composite Index Quarterly Rebalancing
Marketwire Canada - Thu Mar 19, 3:06PM CDT
The quarterly rebalancing of the CSE Composite Index will result in the following changes, effective after the close on Friday, March 20, 2015.
SEE: 46.30 (-0.33), GFI: 4.29 (+0.26), BIS: 31.65 (-0.79), ACH: 16.02 (-1.19), BOI: 16.35 (-0.10)
InMed Initiates Discovery & Pre-clinical Work on Orofacial Pain
Marketwired - Wed Mar 18, 10:01AM CDT
InMed Pharmaceuticals Inc. ("InMed"

(CSE: IN)(OTCQB: IMLFF), a clinical stage biopharmaceutical company that specializes in developing safer, more effective cannabis-based therapies, today announced that it has initiated a program to identify and evaluate cannabinoid compounds for the treatment of chronic orofacial pain. Initial drug discovery and preclinical development is currently underway in collaboration with members of the Faculty of Pharmaceutical Sciences at the University of British Columbia. The work is being funded by a grant from Mitacs, a leading Canadian organization that accelerates innovative projects through strategic academic and industry collaboration.
InMed Forms Strategic Collaboration to Develop Novel Phytocannabinoid Therapies for Ocular Allergies
PR Newswire - Tue Mar 10, 10:00AM CDT
InMed Pharmaceuticals Inc. ("InMed"

(CSE: IN; OTCQB: IMLFF) announces it has formed an exclusive strategic collaboration with the University of Debrecen, Hungary, to develop novel phytocannabinoid-based therapies to treat ocular allergic symptoms. The collaboration will leverage InMed's proprietary Intelligent Cannabinoid Drug Design Platform (IDP) and will be led by one of the world's leading cannabinoid researchers, Dr. Tamas Biro, MD, PhD, DSc. Dr. Biro has extensive research experience in studying the endocannabinoid system (ECS) and the closely related transient receptor potential (TRP) channels in various human diseases.
48 Marijuana Stocks - A Post-Mortem: Part I
Anthony Cataldo - at Seeking Alpha - Tue Mar 03, 1:27AM CST
GWPH: 91.32 (+0.38)
InMed Pharmaceuticals to Present Investor Webcast March 5
CNW Group - Mon Mar 02, 7:30AM CST
Company invites individual and institutional investors as well as advisors to attend interactive real-time presentation at VirtualInvestorConferences.com
A Preliminary Examination Of N=35 Canadian Marijuana Stocks... Eh?
Anthony Cataldo - at Seeking Alpha - Mon Feb 09, 3:20AM CST
InMed Expands Pipeline with Initiation of Program Targeting Epidermolysis bullosa simplex (EBS)
PR Newswire - Tue Feb 03, 5:00AM CST
InMed Pharmaceuticals Inc. ("InMed"

(CSE: IN; OTCQB: IMLFF) announced today that it has added a new therapy to its pipeline: INM-750, for the treatment of Epidermolysis bullosa simplex(EBS), a rare genetically inherited skin disorder. INM-750 is designed to suppress pathological skin growth, differentiation and inflammation that are signature characteristics of EBS.
Marijuana Firms - Exploring N=99, Ranked By Market Capitalization
Anthony Cataldo - at Seeking Alpha - Mon Feb 02, 3:34AM CST
GWPH: 91.32 (+0.38), FULL: 3.55 (-0.03), CARA: 10.93 (+0.27)
Will Strong U.S. Dollar Lead To Canadian/U.S. Marijuana Firm Mergers?
Anthony Cataldo - at Seeking Alpha - Tue Jan 27, 9:36AM CST
12 Marijuana Stocks For Your Do Not 'Buy And Hold' List - Part VII
Anthony Cataldo - at Seeking Alpha - Fri Jan 23, 1:56PM CST
INSY: 57.97 (+0.06), GWPH: 91.32 (+0.38), FULL: 3.55 (-0.03), LINE: 11.66 (+0.21), BAR: 27.30 (-0.07)